Precision Oncology OncoPrecision specializes in first-in-class antibody-drug conjugates and bispecific antibodies for hard-to-treat cancers, presenting a compelling entry point for partnerships with biopharma companies seeking differentiated oncology assets and novel mechanisms.

Innovative Platform The integration of Patient Micro-Avatars with AI-driven target validation and billions of phenotypic data points creates a unique discovery engine. This can accelerate partner programs by de-risking target selection and shortening development timelines.

Clinical Readiness Lead program ONC001 targets CD64 to eliminate leukemic monocytes and tumor-associated macrophages and is advancing through IND-enabling studies, indicating near-term collaboration opportunities in translational and early clinical development with partner support.

Funding & Growth With seed financing totaling over $11 million and revenue in the low to mid single digits, OncoPrecision is a lean, venture-backed biotech poised for collaboration, licensing, or co-development deals to expand its pipeline and de-risk shared programs.

Engagement Readiness Active participation in major scientific events (ASH) and a clear regulatory/clinical pathway signal readiness for partner-led validation studies, joint presentations, or sponsored research agreements to validate and scale ONC001 and future programs.